SCRI Announced a Collaboration with AstraZeneca
In February 2024, SCRI announced a collaboration with AstraZeneca to advance innovative technology and operational
synergies to enhance the delivery of oncology clinical trials. Working together, SCRI and AstraZeneca will implement
modern solutions to accelerate clinical trial delivery timelines, reduce site burden, and enhance U.S. enrollment.
"Improving end-to-end research operations
will have great impact on the industry's ability
to increase the pace of drug development, without compromising quality,"
said Dee Anna Smith, Chief Executive Officer, SCRI. "Our collaboration with
AstraZeneca has the potential to accelerate our mutual efforts to bring novel
therapies to more people with cancer, through more physicians, across even
more communities."
